Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0008 0.00 (0.00%)
As of 09/11/2026
Compare

EFTR vs. NAVB, ADTX, GNCA, PXMD, and ARDS

Should you buy eFFECTOR Therapeutics stock or one of its competitors? eFFECTOR Therapeutics's main competitors and comparable companies include Navidea Biopharmaceuticals (NAVB), Aditxt (ADTX), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does eFFECTOR Therapeutics compare to Navidea Biopharmaceuticals?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Navidea Biopharmaceuticals Neutral

eFFECTOR Therapeutics has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Navidea Biopharmaceuticals beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Aditxt?

Aditxt (NASDAQ:ADTX) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

eFFECTOR Therapeutics has lower revenue, but higher earnings than Aditxt. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.42-$41.71M-$100.79 thousandN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Aditxt has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

eFFECTOR Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. eFFECTOR Therapeutics' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
eFFECTOR Therapeutics N/A N/A N/A

In the previous week, Aditxt's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Aditxt Neutral
eFFECTOR Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
eFFECTOR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

eFFECTOR Therapeutics beats Aditxt on 8 of the 11 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Genocea Biosciences has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market.

eFFECTOR Therapeutics' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
eFFECTOR Therapeutics N/A N/A N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
eFFECTOR Therapeutics Neutral

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

eFFECTOR Therapeutics beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

eFFECTOR Therapeutics' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
eFFECTOR Therapeutics N/A N/A N/A

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
eFFECTOR Therapeutics Neutral

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PaxMedica is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Summary

eFFECTOR Therapeutics beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
eFFECTOR Therapeutics Neutral

Aridis Pharmaceuticals has a beta of 49.95, suggesting that its share price is 4,895% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

Aridis Pharmaceuticals beats eFFECTOR Therapeutics on 5 of the 6 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4K$12.52B$7.20B$12.67B
Dividend YieldN/A2.64%2.57%11.71%
P/E Ratio0.00797.25275.0225.43
Price / SalesN/A756.92638.0888.25
Price / CashN/A14.8628.4234.96
Price / Book0.0010.4210.326.23
Net Income-$35.81M$2.84B$3.50B$358.31M
7 Day PerformanceN/A-3.55%-2.41%-1.59%
1 Month PerformanceN/A0.79%0.22%-2.89%
1 Year PerformanceN/A3.89%24.17%8.22%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A10
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
ADTX
Aditxt
0.1464 of 5 stars		$0.01
+7.4%		N/A-100.0%$6K$14.34KN/A60
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
-28.6%		N/A+400.0%$6KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 9/14/2026 by MarketBeat.com Staff.
From Our Partners
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
Every Major Market Reset Had These 3 Warning Signs First. All 3 Are Flashing Right Now.
U.S. debt is closing in on 38 trillion as foreign buyers pull back, tightening liquidity across markets. Th...
Golden Crest Metals | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The Flaw Your Financial Advisor Will Not Name
The U.S. government values its gold at $42 an ounce, a price set by Congress in 1973 and never updated. Gold t...
Monetary Gold | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel